Haier Biotech announced that in the first half of 2026, it achieved operating income of 1,296 billion yuan, an increase of 8.45% year on year; net profit attributable to shareholders of listed companies was 147 million yuan, up 3.28% year on year; and net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 138 million yuan, an increase of 11.39% year on year. Basic earnings per share were $0.47, up 4.44% year over year. R&D investment accounted for 13.31% of revenue, a year-on-year decrease of 0.08 percentage points. As of the end of the reporting period, the company's special securities account held 3.6541 million shares, accounting for 1.15% of the total share capital. There are no profit distribution plans for the reporting period.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.